Gabapentin, a prescription nerve-pain and seizure drug, may support a memory-loss claim if you filled six or more prescriptions and later developed dementia. Firms focus on mild cognitive impairment or dementia diagnosed before age 65 and confirmed by a neurologist, with no class settlement paying claims now. Pending suits focus on missing long-term warnings for repeated use, according to Miller & Zois. A 2025 cohort study supplies the risk signal firms use for screening, but it does not prove cause.
Official resources:
- Read the official guidance from NIH — Use this primary source to verify the official guidance.
- Check eligibility on Robertkinglawfirm’s official study page — Use this page to check the study’s participation requirements.
Table of Contents
- What the lawsuits claim
- Who firms will screen for a claim?
- Why six prescriptions and age 65 matter
- Is there a settlement now?
- What to do next
What the lawsuits claim
Gabapentin is FDA-approved only for narrow uses such as postherpetic neuralgia and adjunctive partial-onset seizures, according to the National Library of Medicine DailyMed label. Much chronic-back-pain prescribing examined in the study was off-label.
Miller & Zois reports pending lawsuits allege manufacturers failed to warn doctors and patients about long-term cognitive risks. The suits focus on repeated off-label use where benefit was uncertain.
Who firms will screen for a claim?
Firms screening memory-loss claims generally seek six or more gabapentin prescriptions plus a later dementia, mild cognitive impairment, or severe documented memory-loss diagnosis, according to King Law in its gabapentin lawsuit screening update. They often require onset before age 65 with neurologist or specialist confirmation.
Check these patterns from firm screening: Mild cognitive impairment means early memory and thinking problems beyond normal aging. It does not meet dementia criteria but signals higher risk and needs testing.
- six or more gabapentin fills in pharmacy records
- later dementia, mild cognitive impairment, or severe documented memory loss
- diagnosis often before age 65
- neurologist or specialist diagnosis, not self-reported forgetfulness
Why six prescriptions and age 65 matter
The July 2, 2025 analysis in BMJ Regional Anesthesia & Pain Medicine compared 26,414 matched adults with chronic low back pain. It found six or more prescriptions linked to 29% higher dementia and 85% higher mild cognitive impairment within 10 years in its 10-year risk findings. The Fisher Center for Alzheimer's Research Foundation says researchers used TriNetX records from 68 U.S.
health groups from 2004 to 2024. It says risk centered in adults under 65, framing the issue as early-onset impairment in its summary of the age pattern and limits. That same Fisher Center summary calls the study observational. It shows association only and does not prove gabapentin causes dementia.
Is there a settlement now?
There is no federal multidistrict litigation or class settlement for gabapentin-dementia claims as of fall 2026, according to Miller & Zois in its October case-status report. Claims are being screened as individual cases. Philadelphia created a state-court gabapentinoid mass-tort program on Sept.
8, 2026. That program reported 28 gabapentin and pregabalin cases by Oct. 13.
What to do next
Miller & Zois advises potential claimants to preserve pharmacy and neurology records. It also advises seeking attorney case review promptly to protect deadlines.
Do not stop gabapentin abruptly to preserve a claim. Withdrawal and seizure risks require medical supervision, so ask your prescriber before changing dose.